Skip to content
FLFunding Landscape
Open·Ingested 278 days ago, not re-verified since

Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Oct 23, 2025
Amount
$5,500,000
Closes
Oct 11, 2026 (in 74 days)

Classification and identifiers

Solicitation number
RFA-MH-27-135
Assistance listing (CFDA)
93.242

Amount

$5,500,000

Who can apply

For-profitsTribal governmentsSpecial districtsState governmentsPrivate universitiesSmall business

State government agencies, Private colleges and universities, and Small businesses can all apply here. Check the eligibility details below to see if your organization fits.

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

About this opportunity

The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.

Related opportunities

Refine this search